8-K Announcements
6Material company update
Dec 30, 2025·SEC
Material company update
Dec 12, 2025·SEC
Material company update
Dec 9, 2025·SEC
Merus N.V.(MRUS)Earnings, Financials & Key Ratios
MRUS•NASDAQ
$90.00
$6.83B mkt cap·Price updated May 1, 2026
AboutMerus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Show more
- Revenue$35M-12.4%
- EBITDA-$260M-86.6%
- Net Income-$208M-48.1%
- EPS (Diluted)-3.35-11.7%
- Gross Margin37.15%-49.5%
- EBITDA Margin-746.12%-112.9%
- Operating Margin-752.96%-111.4%
- Net Margin-595.93%-69.0%
- ROE-41.39%+11.0%
- ROIC-74.61%+3.1%
- Debt/Equity0.02-55.2%
MRUS Key Insights
Merus N.V. (MRUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 86 (top 14%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 24.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MRUS Price & Volume
Merus N.V. (MRUS) stock price & volume — 10-year historical chart
Loading chart...
MRUS Growth Metrics
Merus N.V. (MRUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years38.92%
5 Years4.68%
3 Years-6.84%
TTM55.9%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-36.92%
Return on Capital
10 Years-47.36%
5 Years-38.34%
3 Years-44.57%
Last Year-48.43%
MRUS Recent Earnings
Merus N.V. (MRUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q4 2025Latest
Oct 31, 2025EPS
$1.23
Est $1.23
+0.0%
Revenue
$10M
Est $9M
+15.8%
Q3 2025
Aug 5, 2025EPS
$2.23
Est $1.17
-90.6%
Revenue
$9M
Est $10M
-10.1%
Q2 2025
May 7, 2025EPS
$1.40
Est $1.16
-20.7%
Revenue
$29M
Est $7M
+289.8%
Q1 2025
Feb 27, 2025EPS
$0.41
Est $0.89
+53.9%
Revenue
$9M
Est $11M
-10.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Oct 31, 2025 | $1.23vs $1.23+0.0% | $10Mvs $9M+15.8% |
| Q3 2025 | Aug 5, 2025 | $2.23vs $1.17-90.6% | $9Mvs $10M-10.1% |
| Q2 2025 | May 7, 2025 | $1.40vs $1.16-20.7% | $29Mvs $7M+289.8% |
| Q1 2025 | Feb 27, 2025 | $0.41vs $0.89+53.9% | $9Mvs $11M-10.5% |
Based on last 12 quarters of dataView full earnings history →
MRUS Peer Comparison
Merus N.V. (MRUS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZYME | 2.05B | 27.61 | -25.56 | 38.87% | -76.56% | -26% | 0.07 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 RGEN | 7.09B | 125.76 | 146.23 | 16.36% | 6.73% | 2.46% | 0.33 |
Compare MRUS vs Peers
Merus N.V. (MRUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRUS Income Statement
Merus N.V. (MRUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.51M | 21.91M | 33.5M | 27.76M | 24.51M | 43.15M | 38.84M | 39.81M | 34.88M | 51.17M |
| Revenue Growth % | 31.76% | 773.11% | 52.86% | -17.15% | -11.69% | 76.02% | -9.99% | 2.5% | -12.38% | 55.9% |
| Cost of Goods Sold | 18.42M | 34.13M | 47.81M | 49.64M | 57.33M | 86.27M | 9.95M | 10.5M | 21.92M | 162.48M |
| COGS % of Revenue | 734.02% | 155.72% | 142.7% | 178.85% | 233.91% | 199.94% | 25.63% | 26.38% | 62.85% | - |
| Gross Profit | -15.91M▲ 0% | -12.21M▲ 23.3% | -14.31M▼ 17.2% | -21.88M▼ 53.0% | -32.82M▼ 50.0% | -43.12M▼ 31.4% | 28.88M▲ 167.0% | 29.31M▲ 1.5% | 12.96M▼ 55.8% | -111.3M▲ 0% |
| Gross Margin % | -634.02% | -55.72% | -42.7% | -78.85% | -133.91% | -99.94% | 74.37% | 73.62% | 37.15% | -217.5% |
| Gross Profit Growth % | -11.47% | 23.28% | -17.17% | -52.97% | -49.99% | -31.37% | 166.98% | 1.46% | -55.78% | - |
| Operating Expenses | 11.97M | 23.09M | 25.62M | 30.41M | 29.29M | 35.93M | 178.34M | 171.11M | 275.58M | 220.34M |
| OpEx % of Revenue | 476.77% | 105.37% | 76.49% | 109.56% | 119.5% | 83.28% | 459.21% | 429.84% | 790.11% | - |
| Selling, General & Admin | 4.83M | 14.32M | 25.62M | 28.8M | 29.29M | 35.93M | 48.75M | 54.2M | 79.96M | 88.31M |
| SG&A % of Revenue | 192.23% | 65.37% | 76.49% | 103.78% | 119.5% | 83.28% | 125.52% | 136.15% | 229.24% | - |
| Research & Development | 18.42M | 34.13M | 52.17M | 53.65M | 62.25M | 94.44M | 148.23M | 132.75M | 229.9M | 306.31M |
| R&D % of Revenue | 734.02% | 155.72% | 155.73% | 193.3% | 253.95% | 218.88% | 381.68% | 333.49% | 659.14% | - |
| Other Operating Expenses | -11.28M | -25.36M | -52.17M | -52.05M | -62.25M | -94.44M | -18.64M | -15.85M | -34.28M | -3M |
| Operating Income | -27.88M▲ 0% | -35.3M▼ 26.6% | -39.93M▼ 13.1% | -52.29M▼ 31.0% | -62.11M▼ 18.8% | -79.05M▼ 27.3% | -149.46M▼ 89.1% | -141.8M▲ 5.1% | -262.63M▼ 85.2% | -331.64M▲ 0% |
| Operating Margin % | -1110.8% | -161.09% | -119.19% | -188.41% | -253.41% | -183.22% | -384.84% | -356.22% | -752.96% | -648.06% |
| Operating Income Growth % | -20.64% | -26.62% | -13.11% | -30.96% | -18.78% | -27.27% | -89.06% | 5.12% | -85.21% | - |
| EBITDA | -27.65M | -34.98M | -39.27M | -51.28M | -60.93M | -77.75M | -148.26M | -139.5M | -260.24M | -329.45M |
| EBITDA Margin % | -1101.47% | -159.63% | -117.23% | -184.75% | -248.59% | -180.2% | -381.75% | -350.44% | -746.12% | -643.78% |
| EBITDA Growth % | -20.63% | -26.54% | -12.25% | -30.58% | -18.83% | -27.6% | -90.69% | 5.91% | -86.55% | -57.54% |
| D&A (Non-Cash Add-back) | 234K | 318K | 658.17K | 1.01M | 1.18M | 1.3M | 1.2M | 2.3M | 2.39M | 2.19M |
| EBIT | -26.39M | -34.26M | -39.93M | -50.69M | -62.11M | -79.05M | -149.46M | -141.8M | -262.63M | -325.86M |
| Net Interest Income | 92.55K | 1.11M | 2.13M | 1.89M | 300K | -129K | 2.72M | 14.51M | 30.79M | 30.35M |
| Interest Income | 92.55K | 1.33M | 2.13M | 1.89M | 300K | 0 | 2.72M | 14.51M | 30.79M | 30.35M |
| Interest Expense | 0 | 227.94K | 0 | 0 | 0 | 129K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -19.56M | -29.22M | 15.4M | 3.3M | -7.48M | 20.56M | 27.83M | 4.35M | 62.64M | 6.71M |
| Pretax Income | -47.44M▲ 0% | -64.53M▼ 36.0% | -24.53M▲ 62.0% | -48.99M▼ 99.7% | -69.59M▼ 42.0% | -58.49M▲ 15.9% | -121.63M▼ 107.9% | -137.45M▼ 13.0% | -199.99M▼ 45.5% | -324.94M▲ 0% |
| Pretax Margin % | -1889.92% | -294.43% | -73.23% | -176.52% | -283.91% | -135.58% | -313.17% | -345.3% | -573.37% | -634.96% |
| Income Tax | 0 | 249K | 178.94K | 172.95K | 411.75K | 209.99K | 895.61K | 2.89M | 7.87M | 9.97M |
| Effective Tax Rate % | 0% | -0.39% | -0.73% | -0.35% | -0.59% | -0.36% | -0.74% | -2.1% | -3.93% | -3.07% |
| Net Income | -47.44M▲ 0% | -64.77M▼ 36.5% | -24.71M▲ 61.8% | -49.17M▼ 99.0% | -70M▼ 42.4% | -58.7M▲ 16.1% | -122.52M▼ 108.7% | -140.34M▼ 14.5% | -207.85M▼ 48.1% | -334.9M▲ 0% |
| Net Margin % | -1889.92% | -295.57% | -73.77% | -177.15% | -285.59% | -136.06% | -315.48% | -352.56% | -595.93% | -654.43% |
| Net Income Growth % | -103.98% | -36.55% | 61.85% | -98.96% | -42.37% | 16.14% | -108.71% | -14.55% | -48.1% | -50.28% |
| Net Income (Continuing) | -47.44M | -64.77M | -24.71M | -49.17M | -70M | -58.7M | -122.52M | -140.34M | -207.85M | -334.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.75▲ 0% | -3.81▼ 1.6% | -1.28▲ 66.4% | -2.28▼ 78.1% | -2.92▼ 28.1% | -1.73▲ 40.8% | -2.92▼ 68.8% | -3.00▼ 2.7% | -3.35▼ 11.7% | -4.43▲ 0% |
| EPS Growth % | -127.27% | -1.6% | 66.4% | -78.13% | -28.07% | 40.75% | -68.79% | -2.74% | -11.67% | -36.92% |
| EPS (Basic) | -3.75 | -3.81 | -1.28 | -2.28 | -2.92 | -1.73 | -2.92 | -3.00 | -3.35 | - |
| Diluted Shares Outstanding | 13.23M | 19.2M | 22.29M | 24.22M | 29.26M | 38.64M | 44.92M | 51.61M | 64.22M | 75.68M |
| Basic Shares Outstanding | 13.23M | 19.2M | 22.29M | 24.22M | 29.26M | 38.64M | 44.92M | 51.61M | 64.22M | 75.68M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MRUS Balance Sheet
Merus N.V. (MRUS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 74.8M | 225.7M | 223.79M | 247.37M | 217.99M | 424.18M | 306.44M | 368.81M | 569.07M | 590.76M |
| Cash & Short-Term Investments | 59.86M | 220.41M | 215.74M | 239.76M | 207.75M | 410.43M | 290.23M | 355.18M | 537.03M | 542.95M |
| Cash Only | 59.86M | 179.57M | 164.43M | 197.61M | 163.08M | 241.44M | 147.75M | 205.05M | 293.29M | 313.76M |
| Short-Term Investments | 0 | 40.84M | 51.31M | 42.15M | 44.67M | 168.99M | 142.48M | 150.13M | 243.73M | 229.19M |
| Accounts Receivable | 1.23M | 3.78M | 4.86M | 2.65M | 1.75M | 6.67M | 4.7M | 3.98M | 4.71M | 19.41M |
| Days Sales Outstanding | 179.39 | 62.9 | 52.92 | 34.88 | 26.04 | 56.45 | 44.15 | 36.5 | 49.29 | 110.77 |
| Inventory | 12.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 246.84 | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 113.58K | 0 | 1.08M | 1.38M | 1.06M | 2.17M | 2.2M | 727K | 1.72M | 5.51M |
| Total Non-Current Assets | 1.25M | 10.4M | 26.18M | 16.01M | 13.22M | 32.42M | 70.1M | 86.68M | 213.62M | 181.23M |
| Property, Plant & Equipment | 681.5K | 1.4M | 2.77M | 8.93M | 8.02M | 7.28M | 24.84M | 23.5M | 20.02M | 19.63M |
| Fixed Asset Turnover | 3.68x | 15.64x | 12.10x | 3.11x | 3.06x | 5.92x | 1.56x | 1.69x | 1.74x | 2.51x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 393.34K | 374.31K | 2.8M | 2.88M | 2.84M | 2.35M | 1.95M | 1.8M | 1.68M | 1.49M |
| Long-Term Investments | 0 | 8.47M | 19.38M | 2.01M | 0 | 20.3M | 36.46M | 57.31M | 187.01M | 710.67M |
| Other Non-Current Assets | 175.63K | 154.76K | 1.23M | 1.91M | 1.95M | 2.08M | 4.81M | 2.87M | 953K | 10.5M |
| Total Assets | 76.05M▲ 0% | 236.11M▲ 210.5% | 249.96M▲ 5.9% | 263.38M▲ 5.4% | 231.22M▼ 12.2% | 456.6M▲ 97.5% | 376.54M▼ 17.5% | 455.49M▲ 21.0% | 785.13M▲ 72.4% | 771.99M▲ 0% |
| Asset Turnover | 0.03x | 0.09x | 0.13x | 0.11x | 0.11x | 0.09x | 0.10x | 0.09x | 0.04x | 0.06x |
| Asset Growth % | 95.97% | 210.47% | 5.87% | 5.37% | -12.21% | 97.48% | -17.53% | 20.97% | 72.37% | 119.24% |
| Total Current Liabilities | 8.15M | 22.46M | 33.14M | 36.79M | 46.75M | 71.9M | 78.93M | 69.09M | 87.08M | 74.11M |
| Accounts Payable | 2.3M | 3.43M | 3.24M | 3.03M | 3.13M | 13.24M | 9.83M | 4.6M | 4.16M | 7.17M |
| Days Payables Outstanding | 45.53 | 36.64 | 24.73 | 22.27 | 19.9 | 56.01 | 360.62 | 159.96 | 69.33 | 23.24 |
| Short-Term Debt | 175.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7M | 2.36M |
| Deferred Revenue (Current) | 1.93M | 8.66M | 19.37M | 18.84M | 20.18M | 34.66M | 29.42M | 22.68M | 29.93M | 104.68M |
| Other Current Liabilities | 231.38K | 535.07K | 207.45K | 21K | 11K | 1.11M | 38K | 35K | 103K | 30.97M |
| Current Ratio | 9.17x | 10.05x | 6.75x | 6.72x | 4.66x | 5.90x | 3.88x | 5.34x | 6.54x | 6.54x |
| Quick Ratio | 7.64x | 10.05x | 6.75x | 6.72x | 4.66x | 5.90x | 3.88x | 5.34x | 6.54x | 6.54x |
| Cash Conversion Cycle | 380.71 | - | - | - | - | - | - | - | - | 87.53 |
| Total Non-Current Liabilities | 32.1M | 156.2M | 111.73M | 95.29M | 82.21M | 68.5M | 50.56M | 30.06M | 47.69M | 36.26M |
| Long-Term Debt | 335.49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 3.87M | 2.52M | 2.26M | 11.79M | 10.49M | 8.21M | 33.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.11M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | -1.11M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 40.26M | 178.65M | 144.87M | 132.08M | 128.95M | 140.4M | 129.49M | 99.15M | 134.77M | 110.36M |
| Total Debt | 511.13K | 0 | 0 | 5.25M | 3.95M | 3.75M | 13.47M | 12.16M | 9.91M | 10.52M |
| Net Debt | -59.35M | -179.57M | -164.43M | -192.36M | -159.13M | -237.68M | -134.28M | -192.88M | -283.38M | -303.24M |
| Debt / Equity | 0.01x | - | - | 0.04x | 0.04x | 0.01x | 0.05x | 0.03x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.92x |
| Interest Coverage | - | -154.87x | - | - | - | -612.81x | - | - | - | - |
| Total Equity | 35.79M▲ 0% | 57.45M▲ 60.5% | 105.09M▲ 82.9% | 131.3M▲ 24.9% | 102.26M▼ 22.1% | 316.2M▲ 209.2% | 247.06M▼ 21.9% | 356.34M▲ 44.2% | 647.93M▲ 81.8% | 661.63M▲ 0% |
| Equity Growth % | 15.67% | 60.52% | 82.93% | 24.94% | -22.12% | 209.2% | -21.87% | 44.24% | 81.83% | 159.21% |
| Book Value per Share | 2.71 | 2.99 | 4.72 | 5.42 | 3.50 | 8.18 | 5.50 | 6.91 | 10.09 | 8.74 |
| Total Shareholders' Equity | 35.79M | 57.45M | 105.09M | 131.3M | 102.26M | 316.2M | 247.06M | 356.34M | 647.93M | 661.63M |
| Common Stock | 1.52M | 2.1M | 2.37M | 2.92M | 3.21M | 4.48M | 4.75M | 5.88M | 6.96M | 6.55M |
| Retained Earnings | -112.84M | -200.93M | -259.45M | -314.6M | -400.11M | -466.93M | -598.12M | -753.06M | -968.39M | -1.13B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 1.59M | 9.07M | -9.22M | -30.45M | -22.53M | -55.47M | 16.61M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRUS Cash Flow Statement
Merus N.V. (MRUS) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.06M | -44.88M | -46.33M | -63.05M | -79.9M | -59.63M | -149.9M | -142.21M | -185.84M | -185.84M |
| Operating CF Margin % | -1078.22% | -204.81% | -138.29% | -227.16% | -325.98% | -138.2% | -385.97% | -357.24% | -532.8% | - |
| Operating CF Growth % | -7.48% | -65.85% | -3.21% | -36.09% | -26.73% | 25.37% | -151.39% | 5.13% | -30.68% | -1543% |
| Net Income | -49.67M | -87.69M | -27.76M | -55.15M | -85.51M | -66.82M | -131.19M | -154.94M | -215.33M | -334.9M |
| Depreciation & Amortization | 246.1K | 381.5K | 729.81K | 1.14M | 1.44M | 1.49M | 1.28M | 2.54M | 2.47M | 2.45M |
| Stock-Based Compensation | 3.48M | 15.37M | 9.07M | 7.83M | 9.37M | 17.09M | 24.54M | 26.23M | 45.83M | 72.01M |
| Deferred Taxes | 20.53M | 31.63M | -7.07M | -89K | -122K | -7K | -1.62M | 842K | -321K | 77K |
| Other Non-Cash Items | -34.7K | -1.25M | -1.35M | -1.6M | 9M | -27.25M | -23.93M | 8.88M | -42.81M | 9.55M |
| Working Capital Changes | -1.62M | -3.33M | -19.94M | -15.18M | -14.08M | 15.87M | -18.97M | -25.75M | 24.32M | -20.21M |
| Change in Receivables | -1.44M | -2.2M | -2.95M | 633K | 1.15M | -4.99M | 1.83M | 1.73M | 1.07M | -17.14M |
| Change in Inventory | 181.94K | 6.23M | -743.54K | 2.29M | 4.13M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -127.25K | 605.85K | 706.93K | 22K | -110K | 10.71M | -3.92M | -3.93M | -136K | 13.11M |
| Cash from Investing | -429.09K | -49.94M | -22.21M | 24.17M | -1.49M | -146.62M | 2.8M | -27.02M | -220.22M | -93.55M |
| Capital Expenditures | -521.64K | -868.58K | -4.21M | -2.6M | -1.29M | -870K | -7.64M | -3.98M | -1.67M | -607K |
| CapEx % of Revenue | 20.78% | 3.96% | 12.56% | 9.36% | 5.25% | 2.02% | 19.67% | 10% | 4.78% | - |
| Acquisitions | 0 | 0 | 0 | 375K | 162.9K | 0 | 52K | 52K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 92.55K | 1.11M | 1.46M | -375K | -162.9K | 0 | -52K | -52K | -163K | 657K |
| Cash from Financing | 52.8M | 223.41M | 60.86M | 74.23M | 39.52M | 281.95M | 58.74M | 230.09M | 494.01M | 354.22M |
| Debt Issued (Net) | -175.63K | -583.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -188.25K | 134.33M | 0 | 48K | 1.45M | 16.85M | 999K | 4.14M | 36.53M | 1.08M |
| Net Change in Cash | 25.31M▲ 0% | 111.29M▲ 339.7% | -6.78M▼ 106.1% | 33.08M▲ 587.6% | -34.53M▼ 204.4% | 78.47M▲ 327.2% | -93.31M▼ 218.9% | 56.58M▲ 160.6% | 89.02M▲ 57.3% | -65.54M▲ 0% |
| Free Cash Flow | -27.59M▲ 0% | -45.75M▼ 65.9% | -50.53M▼ 10.4% | -65.65M▼ 29.9% | -81.19M▼ 23.7% | -60.5M▲ 25.5% | -157.54M▼ 160.4% | -146.19M▲ 7.2% | -187.5M▼ 28.3% | -317.87M▲ 0% |
| FCF Margin % | -1099.01% | -208.78% | -150.84% | -236.52% | -331.23% | -140.22% | -405.64% | -367.24% | -537.58% | -621.16% |
| FCF Growth % | -9.06% | -65.86% | -10.45% | -29.91% | -23.68% | 25.49% | -160.41% | 7.2% | -28.26% | -104.03% |
| FCF per Share | -2.09 | -2.38 | -2.27 | -2.71 | -2.78 | -1.57 | -3.51 | -2.83 | -2.92 | -2.92 |
| FCF Conversion (FCF/Net Income) | 0.57x | 0.69x | 1.87x | 1.28x | 1.14x | 1.02x | 1.22x | 1.01x | 0.89x | 0.95x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 320K | 322K | 635K | 0 | 3.1M | 2.8M | 0 |
MRUS Key Ratios
Merus N.V. (MRUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -142.17% | -138.94% | -30.41% | -41.6% | -59.94% | -28.06% | -43.5% | -46.52% | -41.39% | -50.62% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -547.69% | -117.19% | -77% | -74.61% | -74.61% |
| Gross Margin | -634.02% | -55.72% | -42.7% | -78.85% | -133.91% | -99.94% | 74.37% | 73.62% | 37.15% | -217.5% |
| Net Margin | -1889.92% | -295.57% | -73.77% | -177.15% | -285.59% | -136.06% | -315.48% | -352.56% | -595.93% | -654.43% |
| Debt / Equity | 0.01x | - | - | 0.04x | 0.04x | 0.01x | 0.05x | 0.03x | 0.02x | 0.02x |
| Interest Coverage | - | -154.87x | - | - | - | -612.81x | - | - | - | - |
| FCF Conversion | 0.57x | 0.69x | 1.87x | 1.28x | 1.14x | 1.02x | 1.22x | 1.01x | 0.89x | 0.95x |
| Revenue Growth | 31.76% | 773.11% | 52.86% | -17.15% | -11.69% | 76.02% | -9.99% | 2.5% | -12.38% | 55.9% |
MRUS SEC Filings & Documents
Merus N.V. (MRUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRUS Frequently Asked Questions
Merus N.V. (MRUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Merus N.V. (MRUS) reported $51.2M in revenue for fiscal year 2024. This represents a 9071% increase from $0.6M in 2013.
Merus N.V. (MRUS) saw revenue decline by 12.4% over the past year.
Merus N.V. (MRUS) reported a net loss of $334.9M for fiscal year 2024.
Dividend & Returns
Merus N.V. (MRUS) has a return on equity (ROE) of -41.4%. Negative ROE indicates the company is unprofitable.
Merus N.V. (MRUS) had negative free cash flow of $317.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More MRUS
Merus N.V. (MRUS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates